Other Events ·
At its 2026 Annual Meeting of Stockholders held on June 9, 2026, TELA Bio, Inc. stockholders approved an amendment to…
TELATELA Bio, Inc.
At its 2026 Annual Meeting of Stockholders held on June 9, 2026, TELA Bio, Inc. stockholders approved an amendment to the company's Amended and Restated 2019 Equity Incentive Plan. This amendment increases the authorized shares issuable under the plan by 3,500,000 shares. Additionally, Joseph Capper, Betty Jo Rocchio, and William Plovanic were elected as Class I directors, and the appointment of KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year was ratified. Stockholders also provided non-binding advisory approval for executive compensation. TELA Bio, Inc. is a biotechnology company focused on regenerative medicine.